       Document 0911
 DOCN  M9620911
 TI    Kaposi's sarcoma in patients infected with human virus (HIV): an
       overview.
 DT    9602
 AU    Hermans P; Clumeck N; Division of Infectious Diseases, St. Pierre
       University Hospital,; Brussels, Belgium.
 SO    Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):357-64. Unique Identifier
       : AIDSLINE MED/96059395
 AB    The emergence of Kaposi's sarcoma (KS) among patients with HIV infection
       has raised a number of unsolved questions. The particular epidemiology
       and the etiology of KS remain unclear while both inflammatory cytokines
       and HIV-derived proteins appear to be involved in its pathogenesis as
       shown with the aid of in vitro KS-like cell cultures of animal models.
       Since KS rarely occurs among HIV-positive Caucasian females, sexual
       hormones, especially beta Human Chorionic Gonadotropin, have recently
       been reported as providing theoretically some protection against KS both
       in vitro and in vivo. All these aspects will be detailed as well as the
       therapeutic approaches which still remain unsatisfactory. So far, there
       is no curative treatment for KS and drug-induced toxicity is the
       limiting factor for the prolonged use of the current approaches.
       Perspectives for therapy will be discussed.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS/EPIDEMIOLOGY
       Cytokines/ADVERSE EFFECTS  Cytomegalovirus Infections/COMPLICATIONS
       Female  Human  Incidence  Interferons/PHARMACOLOGY  Male  Sarcoma,
       Kaposi's/*COMPLICATIONS/DRUG THERAPY/EPIDEMIOLOGY  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

